Mithrl raised $20 million in a Series A funding round led by Obvious Ventures to expand deployment of its “biomedical world model” across biopharma R&D. The company said its platform—Mithrl-1—combines curated validated biology with agentic AI for hypothesis generation and routing, and it is launching an early access program for a second-generation system.